DocGo Appoints Healthcare Visionary Dr. Stephen K. Klasko as Chair of the Board
DocGo Inc. (Nasdaq: DCGO) has appointed Dr. Stephen K. Klasko as the new independent, non-executive Chair of its Board of Directors, effective October 1, 2024. Dr. Klasko, a healthcare visionary with extensive leadership experience, will replace outgoing Chair Steven Katz. Dr. Klasko's background includes roles as President of Thomas Jefferson University, CEO of Jefferson Health, and Dean at USF Health and Drexel University College of Medicine.
Dr. Klasko's appointment aims to support DocGo's growth in mobile health initiatives and value-based care strategies. CEO Lee Bienstock expressed excitement about the strategic insight Dr. Klasko brings to the company. The transition comes as DocGo seeks to accelerate its growth and expand its impact in healthcare delivery transformation.
DocGo Inc. (Nasdaq: DCGO) ha nominato Il Dr. Stephen K. Klasko come nuovo Presidente indipendente e non esecutivo del suo Consiglio di Amministrazione, a partire dal 1 ottobre 2024. Il Dr. Klasko, un visionario nel settore sanitario con una vasta esperienza di leadership, sostituirà il Presidente uscente Steven Katz. Il background del Dr. Klasko include ruoli come Presidente della Thomas Jefferson University, CEO della Jefferson Health, e Decano della USF Health e della Drexel University College of Medicine.
La nomina del Dr. Klasko mira a supportare la crescita di DocGo nelle iniziative di salute mobile e nelle strategie di assistenza basate sul valore. Il CEO Lee Bienstock ha espresso entusiasmo per le intuizioni strategiche che il Dr. Klasko porta all'azienda. Il passaggio avviene mentre DocGo cerca di accelerare la sua crescita ed espandere il suo impatto nella trasformazione della prestazione sanitaria.
DocGo Inc. (Nasdaq: DCGO) ha nombrado al Dr. Stephen K. Klasko como nuevo Presidente independiente y no ejecutivo de su Junta Directiva, con efecto a partir del 1 de octubre de 2024. El Dr. Klasko, un visionario en el sector de la salud con una amplia experiencia en liderazgo, reemplazará al Presidente saliente Steven Katz. El historial del Dr. Klasko incluye roles como Presidente de la Universidad Thomas Jefferson, CEO de Jefferson Health y Decano de USF Health y de la Facultad de Medicina de Drexel University.
El nombramiento del Dr. Klasko tiene como objetivo apoyar el crecimiento de DocGo en iniciativas de salud móvil y estrategias de atención basadas en el valor. El CEO Lee Bienstock expresó su entusiasmo por la visión estratégica que el Dr. Klasko aporta a la empresa. La transición se produce mientras DocGo busca acelerar su crecimiento y ampliar su impacto en la transformación de la entrega de atención médica.
DocGo Inc. (Nasdaq: DCGO)는 스티븐 K. 클라스코 박사를 2024년 10월 1일부터 이사회 독립 비상임 의장으로 임명했습니다. 클라스코 박사는 광범위한 리더십 경험을 가진 헬스케어 비전가로서 기존 의장인 스티븐 카츠를 대체하게 됩니다. 클라스코 박사의 경력에는 토마스 제퍼슨 대학교 총장, 제퍼슨 헬스 CEO, USF 헬스 및 드렉셀 대학교 의과대학 학장 등의 역할이 포함됩니다.
클라스코 박사의 임명은 DocGo의 모바일 건강 이니셔티브 및 가치 기반 케어 전략 지원을 목표로 하고 있습니다. CEO 리 비엔스톡은 클라스코 박사가 회사에 제공하는 전략적 통찰력에 대한 기대감을 표명했습니다. 이러한 전환은 DocGo가 성장 속도를 높이고 헬스케어 제공 변화를 확대하려고 하는 시점에 이루어집니다.
DocGo Inc. (Nasdaq: DCGO) a nommé le Dr Stephen K. Klasko en tant que nouveau président indépendant et non exécutif de son conseil d'administration, à compter du 1er octobre 2024. Le Dr Klasko, un visionnaire du secteur de la santé avec une vaste expérience en leadership, remplacera le président sortant Steven Katz. Le parcours du Dr Klasko comprend des rôles en tant que président de l'Université Thomas Jefferson, CEO de Jefferson Health et doyen de l'USF Health et du College of Medicine de l'Université Drexel.
La nomination du Dr Klasko vise à soutenir la croissance de DocGo dans les initiatives de santé mobile et les stratégies de soins basés sur la valeur. Le CEO Lee Bienstock a exprimé son enthousiasme quant aux perspectives stratégiques que le Dr Klasko apporte à l'entreprise. La transition se produit alors que DocGo cherche à accélérer sa croissance et à élargir son impact dans la transformation de la prestation des soins de santé.
DocGo Inc. (Nasdaq: DCGO) hat Dr. Stephen K. Klasko zum neuen unabhängigen, nicht-executiven Vorsitzenden seines Verwaltungsrats ernannt, mit Wirkung zum 1. Oktober 2024. Dr. Klasko, ein visionärer Kopf im Gesundheitswesen mit umfangreicher Führungserfahrung, wird den scheidenden Vorsitzenden Steven Katz ersetzen. Dr. Klaskos Hintergrund umfasst Positionen als Präsident der Thomas Jefferson University, CEO von Jefferson Health und Dekan an der USF Health sowie am College of Medicine der Drexel University.
Die Ernennung von Dr. Klasko zielt darauf ab, das Wachstum von DocGo im Bereich mobiler Gesundheitsinitiativen und wertbasierter Pflege-Strategien zu unterstützen. CEO Lee Bienstock äußerte Begeisterung über die strategischen Einblicke, die Dr. Klasko in das Unternehmen einbringt. Der Wechsel erfolgt, während DocGo bestrebt ist, sein Wachstum zu beschleunigen und seinen Einfluss auf die Transformation der Gesundheitsversorgung auszubauen.
- Appointment of a highly experienced healthcare leader as Board Chair
- Potential for strategic growth in mobile health and value-based care
- Dr. Klasko's prior experience with DocGo through a successful joint venture
- None.
Dr. Klasko has an extensive background in leadership roles within healthcare, higher education and medical industry innovation, including an eight-year tenure as the President of Thomas Jefferson University and the CEO of Jefferson Health where he oversaw its expansion to 18 hospitals and over 35,000 employees. Prior to that, he was CEO of USF Health and Dean of the Morsani College of Medicine at the University of
Dr. Klasko currently serves as a Special Advisor at leading venture capital firm General Catalyst, and as Chief Medical Officer of Abundant Venture Partners. He has sat on the board of directors of Teleflex Incorporated since 2008 where he served on the audit committee and is currently chair of the governance committee and independent Lead Director. His track record of success has earned him accolades over the past several years including Modern Healthcare’s #2 “Most Influential Person in Healthcare” in 2018, one of Fast Company’s “100 Most Creative People in Business 2018”; Ernst & Young’s “Greater Philadelphia Entrepreneur of the Year 2018”; and Becker's Healthcare Review's “Great Leaders in Healthcare” in 2022, 2023 and 2024.
Dr. Klasko has authored several books including UnHealthcare: A Manifesto for Health Assurance with Hemant Taneja, CEO of General Catalyst, which outlines his passion for “healthcare at any address” and actualizing population health. Dr. Klasko was first introduced to DocGo when Jefferson Health formed a joint venture with DocGo’s Ambulnz division, which grew to provide medical transportation services to Jefferson’s eleven hospital locations and is now the largest provider of medical transportation in the
"It is imperative that we transform population health, personalized medicine and social determinants from philosophy to the mainstream of clinical care and payment models," said Dr. Klasko. "I’ve been impressed with DocGo’s vision for mobile health, excited by CEO Lee Bienstock’s entrepreneurial spirit and his vision for DocGo’s leadership in the proactive healthcare revolution. I look forward to partnering with Lee and the DocGo Board to oversee creation of solutions that help improve patient outcomes, make healthcare more affordable and accessible, and deliver on the promise of healthcare at any address."
As non-executive Chair of the Board, Dr. Klasko will assist Mr. Bienstock and the rest of the DocGo Board in steering the company’s efforts to transform healthcare delivery through its mobile health initiatives and value-based care strategies.
"Dr. Klasko’s appointment comes at an exciting time for DocGo as we are well-positioned to accelerate our growth and expand our impact in the healthcare space," said Lee Bienstock, CEO of DocGo. "His strategic insight and proven track record in delivering innovation at scale will be invaluable to the Board as we continue to launch new programs and optimize our value-based care model. I look forward to partnering closely with him and all of our dedicated Board members to drive long-term value for our stakeholders."
Additionally, DocGo CEO Lee Bienstock expressed his gratitude to outgoing Chair Steven Katz, who resigned from the DocGo Board on September 25, 2024, effective as of October 1, 2024: "On behalf of the entire DocGo team, I want to thank Steve for his leadership and dedication as a director, Lead Independent Director, and most recently, Chair of the Board. His guidance was instrumental in helping us navigate through a period of rapid growth and transformation. We are pleased that Steve will remain with DocGo as a consultant to the Company and its Board through the end of the year, to help ensure a smooth transition period."
“DocGo continues to evolve and innovate how healthcare is delivered, and the Company’s rapid growth is a testament to the strength of their approach,” said Steven Katz, outgoing Chair. “I look forward to providing guidance as a consultant to the Company and the Board, and wish the company continued growth and success.”
About DocGo
DocGo is leading the proactive healthcare revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring and ambulance services. DocGo is helping to reshape the traditional four-wall healthcare system by providing high quality, highly accessible care to patients where and when they need it. DocGo’s proprietary technology and relationships with dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient’s home or workplace. Together with DocGo’s integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com. To get an inside look on how the proactive healthcare revolution is helping transform healthcare by reducing costs, increasing efficiency and improving outcomes, visit www.proactivecarenow.com.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the Company’s Board leadership changes as well as the plans, strategies, outcomes, and prospects, both business and financial, of the Company, including its mobile health and value-based care initiatives. These statements are based on the beliefs and assumptions of the Company’s management. Although the Company believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, the Company cannot assure you that it will achieve or realize these plans, intentions, outcomes, results or expectations. Accordingly, you should not place undue reliance on such statements. All statements other than statements of historical fact are forward-looking. In some cases, these statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “might,” “will,” “should,” “could,” “can,” “would,” “design,” “potential,” “seeks,” “plans,” “scheduled,” “anticipates,” “intends” or the negative of these terms or similar expressions. Forward-looking statements are inherently subject to substantial risks, uncertainties and assumptions, many of which are beyond the Company’s control, and which may cause the Company’s actual results or outcomes, or the timing of results or outcomes, to differ materially from those contained in the Company’s forward-looking statements, including, but not limited to the following: the Company’s Board leadership changes; the Company’s ability to successfully implement its business strategy, including its mobile health and value-based care initiatives; the Company’s reliance on and ability to maintain its contractual relationships with its healthcare provider partners and clients; the Company’s ability to compete effectively in a highly competitive industry; the Company’s ability to maintain existing contracts; the Company’s reliance on government contracts; the Company’s ability to effectively manage its growth; the Company’s financial performance and future prospects; the Company’s ability to deliver on its business strategies or models, plans and goals; the Company’s ability to expand geographically; the Company’s competitive position and opportunities, including its ability to realize the benefits from its operating model; and other risk factors included in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements made in this press release are based on events or circumstances as of the date on which the statements are made. The Company undertakes no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as and to the extent required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240930891817/en/
Media:
Tommy Meara
Moxie Strategies
718-309-3506
tommy@moxiestrategies.com
Investors:
Mike Cole
DocGo
949-444-1341
mike.cole@docgo.com
ir@docgo.com
Source: DocGo Inc.
FAQ
Who is the new Chair of DocGo's (DCGO) Board of Directors?
What is Dr. Klasko's background in healthcare leadership?
How might Dr. Klasko's appointment impact DocGo's (DCGO) business strategy?
When does Dr. Klasko's appointment as Chair of DocGo (DCGO) take effect?
